102results about "Coculture" patented technology

A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.

The invention provides methods of treating and preventing loss of tissue vascularization that can occur, for example, upon aging.

Methods of producing stem cell conditioned media to treat mammalian injuries or insults. In at least one embodiment of a method of producing a stem cell conditioned media of the present disclosure, the method comprises the steps of culturing at least one stem cell in a first cell culture medium, replacing some or all of the first cell culture medium with a second cell culture medium and further culturing the at least one stem cell in the second cell culture medium, and collecting a quantity of the second cell culture medium after a culture duration, wherein the quantity of the second cell culture medium contains a cell culture byproduct effective to treat a mammalian insult or injury. In another embodiment, the step of culturing comprises culturing the at least one stem cell in EGM2MV.

Disclosed herein are bioreactor systems and methods of utilizing said systems.

The invention discloses a method for resisting human mesenchymal stem cell aging and enhancing stem characteristics of human mesenchymal stem cells. According to the method, immune cells in human peripheral blood and aged human mesenchymal stem cells are cultured in a cell-to-cell contact mode, the aging characteristics of the aged human mesenchymal stem cells can be remarkably reversed, the expression of cell aging markers such as beta galactosidase, P21 and P16 proteins is reduced, and meanwhile, the cell cycle of the aged human mesenchymal stem cells can be obviously adjusted, specifically,the number of cells in the G1 stage is reduced, and the number of cells in the S stage is increased. More importantly, the method can remarkably enhance the stem characteristics of the aged human mesenchymal stem cells, such as self-renewal capacity, multiplication capacity and multi-directional differentiation potential, and the cells obtained by the culture mode are used for treating disease models and are safe and effective. The method can be directly applied to long-term in-vitro amplification of the human mesenchymal stem cells, the problem of cell aging in the amplification process is solved, the cell activity is recovered, and the clinical application effect is improved.